肝细胞癌:古老和新兴的治疗点
Greta Pessino1, Claudia Scotti1, Maristella Maggi1
1Unit of Immunology and General Pathology, Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.
Cancers
|March 13, 2024
概括
肝细胞癌 (HCC) 治疗由于其复杂的瘤生态系统而面临挑战. 本综述探讨了先进的疗法,如抗体药物合物和CAR-T细胞,重点关注蛋白质组分析和向瘤微环境.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 肝细胞癌 (HCC) 是全球癌症死亡的主要原因,具有多种风险因素,包括非病毒性肝炎和酒精滥用.
- 目前的HCC治疗方法,如化疗和激酶抑制剂,由于复杂的瘤微环境和相关的免疫抑制,具有局限性.
- 没有任何特定的遗传变化与HCC发病有明确的联系,这使得针对性的治疗策略变得复杂.
研究的目的:
- 对肝细胞癌 (HCC) 的现有和新兴治疗策略进行审查.
- 探索新的治疗方法,包括蛋白质组分析衍生的标,抗体药物合物 (ADC),仿真抗原受体T细胞疗法 (CAR-T) 和工程抗体.
- 分析HCC中的关键配体/受体对和分子通路,重点针对瘤微环境,特别是TGFβ.
主要方法:
- 对HCC目前和先进的治疗策略进行系统审查.
- 蛋白质组数据的分析,以确定新的治疗点.
- 评估在HCC瘤细胞中过度表达的连接体/受体对和分子通路.
- 讨论新的方法的潜力和局限性,如ADC,CAR-T疗法,以及针对TGFβ的治疗方法.
主要成果:
- 蛋白质组分析为HCC治疗提供了有希望的新目标.
- 新的策略,如ADCs,CAR-T疗法和工程抗体,显示出增强疗效的潜力.
- 针对特定的连接体/受体对和分子通路,特别是瘤微环境中的TGFβ,为HCC管理提供了一个有前途的途径.
结论:
- 基于蛋白质组分析的先进治疗策略对于克服HCC治疗的挑战至关重要.
- 针对免疫抑制瘤微环境,包括TGFβ等途径,对于改善临床反应至关重要.
- 像ADC和CAR-T疗法这样的新方法代表了HCC治疗的未来,为患者提供了新的希望.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Liver Regeneration
3.3K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
3.3K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166


